(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
China's 1st reusable rocket explodes in dramatic fireball during landing after reaching orbit on debut flight- Argentina reportedly delaying embassy move over Israeli company's oil project near Falklands
- Extravagance SUVs for Seniors: Solace, Innovation, and Security
- 5 Must-Attempt Fascinating Dishes from Around the World
- Twelve injured near Beit Shemesh, reports of shrapnel impact in Eilat as Iran targets Israel
- Rescuers give up hope for the humpback whale stranded in the Baltic Sea
- The Way to Business: Startup Illustrations Learned
- Wisconsin archaeologists identify 16 ancient canoes in a prehistoric lake 'parking lot'
- Arctic sea ice hits lowest winter level as heat records are shattered worldwide
